ReviewBMC infectious diseases2026
Aortoesophageal fistula caused by Mycobacterium bovis following intravesical Bacillus Calmette-Guérin therapy: a case report and literature review.
Review in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravesical Bacillus Calmette-Guérin (BCG) therapy is an established treatment for non-muscle-invasive bladder cancer, involving direct instillation of a solution containing attenuated Mycobacterium bovis into the bladder. Although generally well-tolerated, rare vascular complications, including mycotic aneurysms and aortoenteric fistulas, have been reported. CASE PRESENTATION: We report the case of a 76-year-old Japanese man who developed an aortoesophageal fistula three years after completing intravesical BCG therapy for superficial bladder carcinoma. The patient initially presented with bilateral lower limb pain following thoracic endovascular aortic repair. During hospitalization for lumbar pyogenic spondylitis, M. bovis was isolated from both sputum and spine biopsy cultures and confirmed using single-nucleotide polymorphism analysis. Despite the initiation of antimycobacterial therapy with rifampicin, isoniazid, ethambutol, and levofloxacin, he developed hematemesis and upper abdominal pain. Computed tomography findings were highly suggestive of an aortoesophageal fistula. The patient underwent successful surgical repair followed by a prolonged course of antimycobacterial therapy for at least ten months.
conclusionsTo our knowledge, this is the first documented case of an aortoesophageal fistula caused by M. bovis following intravesical BCG therapy. Clinicians should maintain a high index of suspicion for this life-threatening complication in patients presenting with vascular abnormalities, hematemesis, or abdominal pain following BCG therapy, regardless of the time interval since treatment. Early recognition and aggressive management are essential for improving the outcomes of this rare but life-threatening condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.